Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Optimal timing for hepatitis C therapy in US patients eligible for liver transplantation: a cost-effectiveness analysis.

Alimentary pharmacology & therapeutics - 1 Nov 2016

Njei B, McCarty T R, Fortune B E, Lim J K

Abstract excerpt

BACKGROUND: Recurrence of hepatitis C virus (HCV) following liver transplantation (LT) is universal for those with ongoing viraemia and is associated with higher rates of allograft failure and death. However, the optimal timing of HCV treatment for patients awaiting transplant remains unclear. AIM: To evaluate the comparative cost-effectiveness of treating HCV pre-LT vs. post-LT (pre-emptive or after HCV...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzimidazoles
Share to Cost-Benefit Analysis
Share to Fluorenes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Liver Cirrhosis

Share to Liver Transplantation

Share to Quality-Adjusted Life Years

Share to Ribavirin

Share to Sofosbuvir

Source

Identifiers

PMID: 27640785
DOI: 10.1111/apt.13798

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Optimal timing for hepatitis C therapy in US patients eligible for liver transplantation: a cost-effectiveness analysis.PMID 27640785Read ↗

Timing of hepatitis C antiviral therapy in patients with advanced liver disease: a decision analysis model.Semantic proximity Read ↗

Cost-effectiveness of Ombitasvir/Paritaprevir/Ritonavir, Dasabuvir+Ribavirin for US Post-Liver Transplant Recurrent Genotype 1 HCV.Semantic proximity Read ↗

Cost-effectiveness analysis of antiviral treatment in liver transplant recipients with HCV infection.Semantic proximity Read ↗

Persistence of Virologic Response after Liver Transplant in Hepatitis C Patients Treated with Ledipasvir / Sofosbuvir Plus Ribavirin Pretransplant.Semantic proximity Read ↗

Outcome of early vs. deferred antiviral treatment for recurrent hepatitis C in liver transplant recipients.Semantic proximity Read ↗

Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study.Semantic proximity Read ↗

Sofosbuvir and simeprevir for treatment of hepatitis C virus infection in liver transplant recipients.Semantic proximity Read ↗

Hepatitis C treatment in patients on the liver transplant waiting list.Semantic proximity Read ↗

Long-term results and modeling to predict outcomes in recipients with HCV infection: results of the NIDDK liver transplantation database.Semantic proximity Read ↗

Sofosbuvir-Based Antiviral Therapy Is Highly Effective In Recurrent Hepatitis C in Liver Transplant Recipients: Canadian Multicenter "Real-Life" Experience.Semantic proximity Read ↗

Daclatasvir and Sofosbuvir With or Without Ribavirin in Liver Transplant Recipients: A Single-Center Real-World Study.Semantic proximity Read ↗

Prevention of progression to cirrhosis in hepatitis C with fibrosis: effectiveness and cost effectiveness of sequential therapy with new direct-acting anti-virals.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.